Treatment outcome according to tumor RAS mutation status in TRICOLORE trial: A randomized phase 3 trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer-MedSci.cn

Treatment outcome according to tumor RAS mutation status in TRICOLORE trial: A randomized phase 3 trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer

Komatsu, Y; Takashima, A; Denda, T; Gamoh, M; Iwanaga, I; Shimodaira, H; Nakamura, M; Yamaguchi, T; Takahashi, H; Kobayashi, K; Tsuda, M; Kobayashi, Y; Baba, H; Kotake, M; Ishioka, C; Sato, A; Yuki, S; Morita, S; Takahashi, S; Shimada, K

ANNALS OF ONCOLOGY, 2017; 28 ( ):

科室
- - 订阅+
  - 更多科室
工具
服务